[A prognostic model of intrahepatic cholangiocarcinoma after curative intent resection based on Bayesian network].
C Chen(First Affiliated Hospital of Xi'an Jiaotong University), Zhaohui Tang(Shanxi Agricultural University), J W Zhang(Northwestern Polytechnical University), Hong Wu(Sichuan University), Qi Li(First Affiliated Hospital of Xi'an Jiaotong University), Yinghe Qiu(Second Military Medical University), Bambang Budi Siswanto(Northwestern Polytechnical University), Tianqiang Song(Tianjin Medical University Cancer Institute and Hospital), Zhiqiang Cai(Northwestern Polytechnical University), Xianhai Mao(Hunan Provincial People's Hospital), Yuanyuan He(China Pharmaceutical University), Zhangjun Cheng(Zhongda Hospital Southeast University), Yuxin Wu(Air Force Medical University), Zhimin Geng(Children's Hospital of Zhejiang University), J D Li(GlaxoSmithKline (China)), Wenlong Zhai(Zhengzhou University)
Cited by 2
Related Papers
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
|The Lancet Oncology|2015|1.1k
Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer
|Molecular Cancer|2022|652
Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents
|Gut|2020|578
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
|Clinical Cancer Research|2020|576
Dual targeting luminescent gold nanoclusters for tumor imaging and deep tissue therapy
|Biomaterials|2016|137